DORSAVI LTD — Capital/Financing Update 2026

Mar 16, 2026

==> picture [327 x 53] intentionally omitted <==

17 March 2026

dorsaVi Advances Intelligence at the Ultra Edge with Elite Sport and European Clinical Wins

ViMove+ and onboard Edge AI analytics expand into pharma trials, elite sport and emerging robotics markets.

Key Highlights:

• Select Network surpasses 120 active sites: Expansion into additional US states underway with ViMove+ now live on the Select Hub platform, enabling scalable deployment across physical therapy (physiotherapy) practices.

• Trials with additional franchise physical therapy groups: now commenced and ongoing across the US East Coast, further expanding dorsaVi's clinical network and validating ViMove+ across diverse practice environments.

• Dr. Chirag Patel commercial project confirmed: ESPN Resident Injury Expert and elite sports physician signs commercial terms with dorsaVi to develop new lower limb metrics for NCAA, elite sport, and military applications creating a premium ViMove+ module targeting 2026 revenue.

• European clinical landmark: dorsaVi sensors selected for SEROMA: a pivotal study for Axial Spondyloarthritis (axSpA) across six European sites, led by world-leading rheumatologists, with three global pharma groups already engaged.

• Intelligence at the Ultra Edge: dorsaVi's Onboard Sensor Processing (OSP) capability underpins both deals, a step-change from passive data collection to real-time and on-device AI inference.

• Robotics data opportunity emerging: Clinically validated foot, ankle and spinal biomechanics datasets generated by dorsaVi sensors are increasingly relevant for training and validating locomotion models in next-generation humanoid robotics systems.

• Platform scalability across multiple markets: Technology validated across elite sport and clinical research opens pathways into pharma trials, occupational health, defence and robotics applications.

Melbourne, Australia, 17 March 2026 – dorsaVi Limited (ASX: DVL) (“dorsaVi” or “the Company”) is pleased to announce a series of commercial and clinical milestones that together represent a meaningful acceleration in the Company’s commercial trajectory and technology leadership.

dorsaVi Ltd | ABN: 15 129 742 409 Level 50/108, St Georges Terrace, Perth, WA, 6000 1800 367 728 | dorsaVi.com

The announcements span two distinct but strategically connected agreements, one in elite US sport and one in European clinical research, united by a common technology theme: Intelligence at the Ultra Edge. Both are underpinned by dorsaVi's proprietary Onboard Sensor Processing (OSP) capability, which transforms dorsaVi's wearable sensors from data-capture devices into real-time intelligent systems capable of generating validated, clinical-grade metrics at the point of measurement.

Combined contracted revenue from these new agreements with Dr Patel and Seroma exceeds A$200,000. Management believes these engagements open materially larger addressable markets across pharma, elite sport, occupational health and emerging robotics applications and that the credibility conferred by partners of this calibre accelerates conversations across adjacent markets.

Select Medical Network: Scale, Momentum and Platform Expansion

The Select Medical physical therapy network has now surpassed 100 active sites across the United States, with targeted expansion into new states currently underway. ViMove+ has been integrated directly onto the Select Hub platform, streamlining deployment and deepening the clinical workflow integration that has driven adoption to date.

Trials with additional physiotherapy groups on the US East Coast have commenced and are ongoing. Early engagement data is reinforcing the platform's clinical utility and the willingness of physio practices to adopt objective, sensor-based movement assessment as part of routine care. Management sees the East Coast trial activity as a meaningful pipeline development channel, with structured conversion pathways into the Select model.

Dr. Chirag Patel Commercial Project: Elite Sport and Military Applications

dorsaVi has formalised commercial terms with Dr. Chirag Patel, a prominent US Foot and Ankle Physician, Surgeon, and Resident Injury Expert for ESPN, for an 8-month project to develop a new premium lower-limb analytics module within the ViMove+ platform.

Dr. Patel is Managing Director of New Horizons Foot and Ankle Associates and Founder/CEO of Health AnalySYST. His practice services elite athletes from across the NFL, NBA, MLB, MLS, and USL. The ESPN platform reaches millions of viewers on injury prevention and return-to-play topics — making Dr Patel an exceptional commercial and credibility partner for dorsaVi.

The project builds directly on successful initial research completed in early 2025, which identified optimal sensor positioning on the lower limb for superior algorithmic outputs. The new phase moves from research to commercial product: capturing real-time biomechanical data on athletes during training and competition.

Why This Deal Matters Beyond Revenue

A collaboration with a physician of Dr. Patel's stature at the intersection of elite sport, media and clinical medicine validates dorsaVi's technology in a highly visible context. This creates a halo effect that management expects to accelerate conversations with other sporting bodies, military procurement teams, and adjacent clinical markets.

Foot and ankle biomechanics are among the most data-rich and clinically critical domains in human movement. The sensor data captured in this project — joint angles, load asymmetry, gait patterns, movement efficiency — are precisely the structured, high-resolution movement datasets attracting intense interest from humanoid robotics developers seeking to train and validate locomotion models.

SEROMA / Axial Spondyloarthritis: European Clinical Research Landmark

dorsaVi's sensors and ViMove+ software have been selected, following a competitive review, as the technology platform for the SEROMA project, a landmark European clinical study investigating objective outcome measures for Axial Spondyloarthritis (axSpA).

axSpA is a chronic, progressive inflammatory condition causing pain, stiffness, and loss of spinal function. Despite affecting millions globally, the condition has lacked a reliable, objective clinical measure of disease

dorsaVi Ltd | ABN: 15 129 742 409 Level 50/108, St Georges Terrace, Perth, WA, 6000 1800 367 728 | dorsaVi.com

progression. The current standard, the BASMI index, has recently been downgraded in the ASAS-OMERACT Core Outcome Set due to poor reliability and limited sensitivity. SEROMA is designed to replace it with a validated, sensor-based alternative.

The SEROMA consortium brings together leading European rheumatologists across six clinical sites, with direct involvement of the Assessment of Spondyloarthritis International Society (ASAS), a body representing over 200 axSpA researchers globally. Three global pharmaceutical companies are already engaged, recognising that validated, sensor-based outcome measures are urgently needed for drug approval trials under FDA and EMA frameworks.

Following competitive selection, dorsaVi was chosen for its proven expertise in clinical sensor technology, strong IP, affordable and collaborative business model, and track record of innovation enabling expansion into whole-spine assessment protocols.

Strategic Significance: Europe and the Regulatory Horizon

The selection of dorsaVi by a leading European clinical consortium is well-timed. Europe is establishing new regulatory frameworks governing AI and autonomous systems in healthcare and robotics — frameworks that place a premium on validated, clinically-anchored sensor technology. dorsaVi's participation in landmark studies like SEROMA builds the regulatory track record and European clinical network that will be essential for accessing this growing market.

Once validated, the SEROMA sensor-based outcome measure is expected to be rapidly adopted in global pharmaceutical trials, creating recurring revenue through licensing, service agreements, and platform subscriptions. Beyond pharma, the validated methodology extends across rheumatology and other musculoskeletal conditions, multiplying the addressable market.

Path to Commercialisation

Phase	Milestone	Commercial Outcome
1	Regulatory endorsement via ASAS	Broad clinical adoption; replaces BASMI as gold standard
2	Pharma integration into pivotal axSpA drug trials	Recurring licensing and service revenue
3	Extension across rheumatology and MSK diseases	Multiplied addressable market; academic and clinical uptake

Intelligence at the Ultra Edge: The Technology Unifying Both Deals

The thread connecting the Dr. Patel collaboration and the SEROMA project is not coincidental and it reflects a deliberate technology positioning that management believes is a significant and durable competitive differentiator.

Traditional wearable devices capture raw data and transmit it to cloud infrastructure for processing. The resulting latency makes real-time intervention impossible in elite sport and remote (at home) clinical applications, and limits clinical utility in fast-moving research environments. dorsaVi's Onboard Sensor Processing (OSP) architecture solves this fundamentally: data capture, analysis and interpretation occur directly on the sensor device, enabling immediate transmission of refined, clinically meaningful metrics.

dorsaVi Ltd | ABN: 15 129 742 409 Level 50/108, St Georges Terrace, Perth, WA, 6000 1800 367 728 | dorsaVi.com

Strategic Value — OSP Applications Across Both Deals:

Elite Sport (Dr. Patel)

• Biomechanical alerts during competition

• Fatigue markers and valgus collapse detection in real time

• Proactive injury prevention before athletes are harmed

• Objective coach data for substitutions and load management

Clinical Research (SEROMA)

• Validated spinal mobility metrics at point of assessment

• No cloud dependency — scalable across dispersed trial sites

• Continuous, objective metrics for drug efficacy trials

• Real-world patient performance data for precision medicine

RRAM and Neuromorphic Computing: The Future Fuel for OSP

dorsaVi's investment in neuromorphic computing and Resistive RAM (RRAM) , advanced through the January 2026 collaboration with ITRI (Taiwan) and NTU (Singapore) to the 22-nm technology node, is directly relevant to the commercial pipeline being built today. Both Dr. Patel's elite sport clients and the SEROMA pharma partners are prospective beneficiaries of the step-change in OSP performance these technologies will enable.

Neuromorphic processing, inspired by the architecture of the human brain, is exceptionally well-suited to the pattern-recognition and time-series analysis demands of continuous biomechanical monitoring. RRAM provides ultra-low power, high-speed memory access that makes on-device AI inference feasible in a wearable form factor. The 22-nm program targets compute-in-memory efficiency exceeding 20 TOPS/W, a capability that will materially extend what dorsaVi's sensors can detect and report in real time.

As these capabilities mature, dorsaVi expects to be uniquely positioned to serve markets that currently lack adequate solutions: continuous remote patient monitoring, precision medicine trials, elite sports analytics, and industrial occupational health.

The Robotics Horizon: Why Biomechanics Data Has Emerging Platform Value

Beyond the clinical and sporting markets, dorsaVi's leadership is alert to a longer-horizon opportunity: the role of high-quality human movement data in the development of humanoid robotics.

The global humanoid robotics sector is scaling rapidly with the broader robotics market is projected to reach US$372.59 billion by 2034[1] . A critical bottleneck is the availability of validated, high-resolution biomechanical data, particularly for complex movements such as foot and ankle articulation, spinal flexion, and multi-joint coordination under load.

dorsaVi's clinical-grade sensor data, validated against the gold-standard Vicon system to within 1-2 degrees, is precisely the structured movement dataset that robotics developers require to train, test, and refine locomotion models. The foot and ankle metrics being developed with Dr. Patel, and the spinal mobility data captured in SEROMA, represent sensor data categories of direct relevance to next-generation robotic systems.

European regulatory developments — including emerging frameworks governing AI in healthcare and autonomous robotic systems — further underpin the value of dorsaVi's position as a provider of validated, clinically-anchored sensor technology. The Company's participation in European clinical research through SEROMA establishes exactly the kind of regulatory track record these frameworks will require.

1 https://www.precedenceresearch.com/robotics-technology-market

dorsaVi Ltd | ABN: 15 129 742 409 Level 50/108, St Georges Terrace, Perth, WA, 6000 1800 367 728 | dorsaVi.com

Investment Highlights

Theme	Detail
Revenue Milestone	Combined contracted revenue from Dr Patel and Seroma Agreements exceed A$200,000 across two new commercial agreements
Network Scale	Select Network at 100+ sites; new US states targeted; ViMove+ on Select Hub
Clinical Credibility	Dr. Patel (ESPN) and SEROMA consortium validate dorsaVi at the highest levels of sport and clinical research
Technology Edge	OSP delivers real-time, on-device AI inference — differentiating dorsaVi from all passive data collection competitors
Semiconductor Roadmap	22-nm RRAM/neuromorphic program (ITRI/NTU) targets >20 TOPS/W — direct uplift for OSP in wearables and clinical platforms
Adjacent Markets	Foot/ankle and spinal data relevant to humanoid robotics; European presence aligned with emerging AI/robotics regulation
Platform Scalability	SEROMA methodology extensible across rheumatology and MSK; Dr. Patel halo effect opens elite sport and military pipeline

Mat Regan, Group CEO of dorsaVi, commented:

"The announcements we are making today reflect the culmination of years of disciplined technology investment and clinical relationship-building. Importantly, this is not simply the announcement of two commercial agreements — it demonstrates that our Intelligence at the Ultra Edge strategy is attracting exactly the type of high-credibility, high-potential partners we anticipated.

Dr. Patel is a clinician with a national media platform and relationships across elite US professional sport. The SEROMA consortium represents scientific leadership within a global disease community, with direct connections to pharmaceutical companies and regulatory bodies. Both selected dorsaVi following competitive processes, which we believe reflects the strength of our technology and platform.

Our RRAM and neuromorphic investments represent the natural extension of the OSP capability that is already attracting these clients. As we look further ahead, we see a world where the data our sensors — — generate today foot angles, spine vectors and movement signatures becomes foundational to the next generation of robotics and intelligent physical systems. Our focus is on building toward that future while continuing to deliver commercial outcomes today. ”

This release has been authorised for lodgement to the ASX by the Board of Directors.

- ENDS –

dorsaVi Ltd | ABN: 15 129 742 409 Level 50/108, St Georges Terrace, Perth, WA, 6000 1800 367 728 | dorsaVi.com

For further information about dorsaVi, please contact:

	Mathew Regan Group Chief Executive Officer +61 427 477 298 Email: mregan@dorsaVi.com	Gernot Abl Chairman +61 419 802 653 Email: ga@dorsaVi.com

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi’s focus is on two major markets:

• Workplace: dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company’s customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Boeing, Monash Health, Coles, Woolworths, Toll, Toyota, Orora, Mineral Resources and BHP Billiton.

• Clinical: dorsaVi is transforming the management of patients with its clinical solutions (ViMove+) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refer to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsaVi.com

dorsaVi Ltd | ABN: 15 129 742 409 Level 50/108, St Georges Terrace, Perth, WA, 6000 1800 367 728 | dorsaVi.com